Abstract #1154

Increased spatial resolution of MR Spectroscopic Imaging improves the detectability of metabolic changes in Multiple Sclerosis lesions

Eva Heckova¹, Gilbert Hangel¹, Bernhard Strasser², Michal Považan^3,4, Assunta Dal-Bianco⁵, Paulus Rommer⁵, Elisabeth Springer¹, Stephan Gruber¹, Siegfried Trattnig^1,6, and Wolfgang Bogner^1,6

¹High Field MR Centre, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, ²Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States, ³Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, United States, ⁴F. M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, MA, United States, ⁵Department of Neurology, Medical University of Vienna, Vienna, Austria, ⁶Christian Doppler Laboratory for Clinical Molecular Molecular MR Imaging, Vienna, Austria

MR Spectroscopic Imaging provides the ability to assess the abundance and spatial distribution of several neurometabolites, which are characteristic for pathophysiological processes related to the formation and development of Multiple Sclerosis lesions. In presented work we aimed to compare the detectability of metabolic changes in MS lesions for three different in-plane resolutions of MRSI, i.e. 2.2×2.2 mm², 3.4×3.4 mm² and 6.8×6.8 mm². Our results suggest that the vast majority of metabolic changes in MS cannot be reliably assessed using MRSI with typical matrix sizes of 24x24 to 32x32. With ultra-high spatial resolution (2.2x2.2 mm² in-plane) even very small MS lesions can be well resolved.

This abstract and the presentation materials are available to members only; a login is required.

Join Here